Eric Kelsic

Eric Kelsic is a scientist and entrepreneur leading the transformation of gene therapy through artificial intelligence. As the CEO and Co-founder of Dyno Therapeutics, he is pioneering an AI-powered platform to solve the industry’s greatest bottleneck: the safe and effective in vivo delivery of genetic medicines.

Eric’s work is rooted in a "physics-first" philosophy, viewing biological systems as programmable machines. Prior to founding Dyno, he was a researcher in George Church’s lab at the Wyss Institute of Harvard Medical School, where he led the team that developed Dyno’s core technology. During this time, he published foundational research in Science, measuring the first comprehensive fitness landscape of the AAV capsid and co-discovering the AAV MAAP gene.

Under his leadership, Dyno has raised over $100M in financing (including a Series A led by a16z) and established a dominant partnership network with global leaders like Astellas, Roche, and NVIDIA. Eric holds a PhD in Systems Biology from Harvard University and a BS in Physics from Caltech. He has been recognized as one of Endpoint News’ "20 under 40" next-gen biotech leaders and Xconomy’s Startup Founder of the Year.